Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Operating Income: 2021-2025

Historic Operating Income for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to -$54.0 million.

  • Prime Medicine's Operating Income rose 0.48% to -$54.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$204.0 million, marking a year-over-year increase of 9.87%. This contributed to the annual value of -$202.5 million for FY2024, which is 1.14% up from last year.
  • According to the latest figures from Q3 2025, Prime Medicine's Operating Income is -$54.0 million, which was down 1.12% from -$53.4 million recorded in Q2 2025.
  • Prime Medicine's Operating Income's 5-year high stood at -$10.4 million during Q3 2021, with a 5-year trough of -$68.0 million in Q4 2023.
  • Over the past 3 years, Prime Medicine's median Operating Income value was -$52.4 million (recorded in 2025), while the average stood at -$51.5 million.
  • Data for Prime Medicine's Operating Income shows a peak YoY increase of 35.60% (in 2022) and a maximum YoY decrease of 203.59% (in 2022) over the last 5 years.
  • Over the past 5 years, Prime Medicine's Operating Income (Quarterly) stood at -$60.1 million in 2021, then soared by 35.60% to -$38.7 million in 2022, then plummeted by 75.89% to -$68.0 million in 2023, then spiked by 35.01% to -$44.2 million in 2024, then increased by 0.48% to -$54.0 million in 2025.
  • Its Operating Income was -$54.0 million in Q3 2025, compared to -$53.4 million in Q2 2025 and -$52.4 million in Q1 2025.